Life Sciences Archive » July, 2017

Life Sciences - July, 2017

342 articles

• Dr. Oz-Backed Cos. Can't Escape Suit Over Diet Pills
• SEC Fines Brokerage Firm, Restricts Penny Stock Deposits
• Calistoga Tells Del. Justices Gilead Owes $50M Drug Bonus
• LabCorp. Drops $1.2B To Buy Research Contractor Chiltern
• Deals Rumor Mill: Dow, Fosun Pharmaceutical, Anbang
• Congressional Forecast: August
• T. Rowe, Funds Fight Valeant's Bid To Kill Stock Drop Suits
• Epstein Becker Green Hires FDA Regulatory Lawyer
• Genetic Privacy Row Beats Dismissal Bid Without Class Cert.
• Board-Suspicious Biotech Investors Sue For Records
• Investors Sue Abuse-Deterrent Opioid Co. After FDA Setback
• If The Surgeon's A Robot, Who's The Learned Intermediary?
• Cybersecurity Risks In The Courtroom
• J&J Presses Expert On Talc Studies In Calif. Cancer Trial
• Attys Predict Next Steps After ACA Repeal Failure
• Only 1 Suit Left In Eliquis MDL As 20 More Cases Get Cut
• Shkreli Called A 'Con Man' As Fraud Case Heads To Jury
• PTAB To Review 3 Herceptin Patents In Hospira Challenge
• Health Hires: EBG, Buchalter, Reproductive Rights Center
• Gilead Says Macleods India Infringed HIV Medication Patents
• Families In Zofran MDL Seek Docs About Foreign Regulators
• NJ Appeals Court Revives 2K Cases In Accutane Litigation
• Gray Matters: Clients Are Not Really 'Emotional'
• Sanofi Asks To Go Solo With Its EpiPen Fight Against Mylan
• Colgate Retirees Get Class Cert. In Denied Benefits Row
• Feds Call Shkreli A Liar As Defense Denies Any Fraud
• Del. Vice Chancellor Presses Innoviva On Proxy Deal Drop
• Talc Is Toxic, Expert Says In First Calif. J&J Cancer Trial
• Access To Branded Drug Samples Key To Generics, Reps Hear
• Millennium Labs Judge Grills Sides On 3rd-Party Releases
• Fed. Circ. Affirms PTAB Nix Of Soft Gel Patents
• Fed. Circ. OKs Inequitable Conduct Ruling Against Regeneron
• BioScrip Investors' Attys Win $2.7M In Fees From $11M Deal
• DNA Co., Mother Resolve Baby Sex Test Dispute
• Ex-Insys Execs, Prosecutors Spar Over Patient 'Victims'
• FDA Panel Recommends Against OK'ing Blue-Dye Opioid
• Vet Products Co. Not Covered For TCPA Suit, Judge Rules
• Coca-Cola, Others Must Face Superfund Suit, Ohio Judge Told
• Avoiding The Rotten Compromise In Mass Litigation
• Having A Chief Privacy Officer Reassures Your Firm's Clients
• J&J Hid Talc Cancer Risk To Save Image, Calif. Jury Told
• J&J, DePuy To Face Partly Revived FCA Suit Over Hip Device
• Global Cartel Fines Down In 2017, Report Says
• PTAB Won't Review AstraZeneca's Symbicort Inhaler Patent
• Deals Rumor Mill: JPMorgan, Nature's Bounty, Snapdeal
• Shkreli Loses Bid To Nix Charges After Resting Case
• J&J Wants 5th Circ. To Block Fourth Hip Implant Bellwether
• UC Urges Fed. Circ. To Nix 'Unjust' Gene Editing Patent Ruling
• IRS Brings Transfer Pricing Row With Medtronic To 8th Circ.
• J&J Can't Beat Andover False Ad Suit Over Bandages
• Cancer-Drug Maker Loses 2nd Bid To Duck Stock-Drop Suit
• FDA Raises Safety Concerns With Hep B Vaccine
• ACA Repeal: Deciphering The Path Ahead
• The 9th Circ.'s Expansive Reading Of Escobar In Gilead
• Innovating For Wise Juries: Discussions Before Deliberations
• Combating Securities Fraud Allegations With 10b5-1 Plans
• Altor Bioscience Investors Fail To Halt $290M NantCell Merger
• Shkreli Slams Katten Atty In Emails, As Trial Wraps Up
• FDA Warning Wire: Cancer-Treating Claims On Christian Site
• Accutane Label Didn't Adequately Warn, NJ Panel Says
• Celgene To Pay $280M To End Off-Label Cancer Drug FCA Suit
• Pa. Appeals Court Asked To Lift Cap On Risperdal Damages
• Olympus To Pay $6.6M Over Role In Patient's Deadly Infection
• Ex-Adviser Cops To Trading Scheme With Ex-Hunton Atty
• BakerHostetler Nabs Thompson Hine Life Sciences Patent Atty
• Paul Hastings Atty Joins Latham's White Collar Team
• $5B Parexel Take-Private Deal Incites Investors
• Judge Reverses J&J's Win In Philly Pelvic Mesh Mass Tort
• GOP Narrowly Starts Debate On ACA Repeal
• Stada Boards Back Sweetened €4.12B Bain, Cinven Buyout
• Holland & Knight Adds IP Attorney From Cantor Coburn
• Retailers Seek Docs Given To FTC In Aggrenox MDL
• 5 Questions Firms Should Ask When Evaluating Litigation AFA
• For Law Firm Offices, Business Savvy Is The New Cool
• SEC Wins Bid To Shield Notes From Atty Gone Fraudster
• Democrats Launch New Campaign To Target Rx Drug Costs
• 11 Teva Entities Can't Escape Pa. Generic Price-Fixing Suit
• Dems Embark On Agenda To Limit Mergers, Tax Loopholes
• Merck Launches 2nd Biosimilar Rival To J&J's Remicade
• Janssen, Bayer Must Face Third Bellwether In Xarelto MDL
• Philips Says It's Owed $217M In Defibrillator Patent Row
• Shkreli Says He Won't Take Stand At Securities Fraud Trial
• Mesh Cases Against Boston Scientific Withdrawn From Philly
• Mitsubishi Tanabe Pays $1.1B For Israeli Clinical Drug Co.
• FDA Staff Flags Lack Of Data On Abuse Potential For Opioid
• BPCIA Questions Continue To Arise For Biosimilar Applicants
• AbbVie Must Pay $150M For False AndroGel Ads, Jury Says
• Endologix Seeks Sanctions For Investor's Witness Statements
• The Best Documents In Your Case May Be From 3rd Parties
• Planning A Legal Career With A Future Relocation In Mind
• The Best Law Firms For Female Partners
• The Best Law Firms For Female Attorneys
• 4 Female Perspectives On BigLaw Leadership
• BigLaw Bias Suits New Wild Card In Fight For Gender Equity
• Women See Another Year Of Slow Gains At Law Firms
• How 4 Firms Are Moving The Needle On Gender Diversity
• Could An NFL Diversity Rule Be A BigLaw Game-Changer?
• 7th Circ. Sides With Immigrant In Row Over Marijuana Offense
• Feds' Shkreli Case Nears End, Amid Testy Exchanges
• Jury Begins Deliberations In Suit Over AbbVie's AndroGel
• Hormone Clinic Chain Must Pay $18M Over Safety Claims
• FDA's E-Cig Rule Survives Industry Challenge
• Calif. Nutrition Co. Takes Row Over Wash. Tax To High Court
• Texas Judge Questions Arbitration For 'Indirect Customers'
• Key ACA Repeal Elements Need 60 Votes
• Cherokee Nation Says Opioid Dispute Belongs In Tribal Court
• Drug Info Co. Wants Defense In Bayer's Price Listing Suit
• Illumina, Qiagen Settle DNA Sequencer Patent Dispute
• WilmerHale Must Face 'Freeze-Out' Suit, Appeals Court Says
• Hogan Lovells Snags Veteran HHS, FDA Attorney
• The Elephant In The Room: Advancing Women To Partnership
• How Midsize Law Firms Can Minimize Cybersecurity Threats
• Judge Mulls Privacy Concerns In Utah Drug Records Case
• Ex-ArthroCare CEO Can't Escape Wire Fraud Charges
• Bayer Says 'Flanax' Antitrust Counterclaims Ignore Market
• Pharma Co. Fails In DQ Bid Against Ex-CEO's Counsel
• Amphastar Escapes $1B Momenta, Sandoz Infringement Suit
• High Court Signals Interest In Vitamin C Price-Fix Case
• Is Bankruptcy An Option For Ancillary Marijuana Businesses?
• Jurors Won't Hear Theory J&J Conspired To Hide Talc Danger
• Shkreli, Gov't Embroiled In Investor Evidence Fight
• PTAB Upholds Validity Of 5 Patents For Pfizer's Toviaz
• Amphastar Asks Jury To Nix $1B Momenta Infringement Case
• Study Says Some Antibiotics Up Risk Of Birth Defects
• Greatbatch, AVX Argue Final Details Ahead Of Patent Trial
• Drug, Device Cos. Assail FDA's Off-Label Stance
• FTC Balks At Discovery Extension In AndroGel Antitrust Suit
• Abbott, Fla. Pharmacy Settle 'Gray Market' Test Strip Suit
• Namenda Buyers' Experts Should Stay, Judge Says
• FDA Tentatively OKs Merck Biosimilar To Sanofi Diabetes Drug
• FTC Approves Baxter $625M Claris Buy With Antitrust Fixes
• Abbott Won't Get New Trial After $15M Depakote Verdict
• Doc Charged With Trading Ariad Stock On Wife's Inside Info
• Fed. Circ. Upholds Generics' Win In Abilify Patent Suit
• Ogletree Adds Employment Atty From Morgan Lewis
• Feds Warn Of 'Increasingly Unhinged' Insider Trading Suspect
• Deals Rumor Mill: ADT, Cardinal Health, Adnoc
• WilmerHale Guides $90M IPO For Kala Pharmaceuticals
• Health Data Co. Owner Gets 10 Years For Investor, Tax Frauds
• New E-Cigarette Studies May Prove Key For Litigators
• Catheter Patent Owner Says TC Heartland Can't Sink Suit
• Current Trends In Biologics-Related Inter Partes Reviews
• Unilife Receives Court OK For Sales To Credit Bidders
• FDA Heard All Stories Of AndroGel Heart Attacks, Jury Told
• 5 More AGs Bring Price-Fixing Suit Against Drugmakers
• Shkreli Trial On Hiatus Over Gov't Evidence Gambit
• Major IP Groups Urge Full Fed. Circ. To Eye AIA On-Sale Bar
• DEA Asks DC Circ. To Enact Ban On Opioid Supplier's Sales
• Amphetamine-Laced Supplements Land Florida Exec In Jail
• FDA Policy Analyst Joins Top Generic Drugs Lobby Group
• Surgery Tool Maker Sued Over NJ Woman's Cancer Death
• Fed. Circ. Affirms ITC Infringement Ruling On Dental Patents
• More PTAB Fights Between Big Pharma Could Be Looming
• A Chat With FTC's Thomas Pahl
• Innovating For Wise Juries: Matching Experts
• Shkreli Vowed To Make Trader's Kids Homeless, Jury Hears
• FDA Warning Wire: Donor Screening Lapses At Fertility Clinic
• Teva Employees Say Co. Hid DOJ Antitrust, Bribery Probe
• Sarepta To Pay $35M Plus Royalties In Exondys Patent Dispute
• Consumers Say Merck's Shingles Vaccine Poses Health Risks
• Feds May Appeal 9-Year Sentence In Meningitis Outbreak Case
• HHS Urges More Transparency On 340B Drug Prices
• Ex-FDA Head's Comments May Put Meningitis Cases In Peril
• Atty Stuck With $25K Sanction In Enbrel Discovery Row
• Class Attys Seek $20M In Fees In Merck Pay-For-Delay MDL
• The Rise Of Midsize Firms
• Daubert And Product Liability: Mid-2017 Update — Part 2
• 5 Questions To Ask Yourself Before Submitting Litigation AFA
• Shkreli Investor Irked By Loss, But Then Cashed In Big
• Drug Costs Threaten FDA Quick Approval Program, Docs Say
• Gilead Backs Chancery In Appeal Of $50M Merger Bonus Suit
• Reed Smith Widow Fires Back At GSK Bid For New Trial
• Drug Return Fraudster Fights Forfeiture Bid
• AndroGel Benefits Not Worth Cardiac Risk, Jury Hears
• Venable Adds Ex-Pfizer Lawyer To FDA Practice In DC Office
• RI Atty Must Face Fee Dispute Suit In Texas, Court Affirms
• Gilead Wins $14M In Attys' Fees For Merck Patent Misconduct
• FDA Rejects Amgen Osteoporosis Drug, Asks For Safety Info
• 4 M&A Partners Join Nixon Peabody's New NC Office
• Ex-Fox Rothschild Partner Heads To Generic Drug Co. As GC
• Fed. Circ. Revives Axed Millennium Cancer Drug Patent
• EU Says Teva, Cephalon Deal Violated Antitrust Rules
• How Mobile Apps Can Benefit Your Practice
• J&J Escapes Suit Over Talc-Based Baby Powder
• A More Consistent USPTO Approach To Patent Eligibility
• Daubert And Product Liability: Mid-2017 Update — Part 1
• The Future Of Litigation Finance Is Analytics
• Law360 Names Top Attorneys Under 40
• Retrophin CEO Was Told Of Shady Shkreli Deals, Jury Hears
• AbbVie Needed To Study Heart Impact Of AndroGel, Jury Told
• BCBS Units Sue Insys Over Off-Label Fentanyl Rx Scheme
• Non-Missourians Kicked Out Of Bayer Essure Suit
• 6 Firms To Steer Nearly $1B In IPOs As Deals Perk Up
• Health Hires: Cozen O'Connor, King & Spalding, West Health
• Unilife Committee Says Sale Plan Cuts It Out Of Recovery
• Salk Institute Sued By Top Scientists For Gender Bias
• PTAB Nixes Patent Claims UPenn Said Erbitux Infringed
• Ionis Subsidiary Akcea Therapeutics Prices $125M IPO
• Specific Personal Jurisdiction: The Unanswered Questions
• Lilly Settles Cialis Generic Patent Suit, Cuts Exclusivity
• 'Jury's Still Out' On CRISPR Patent Licensing Pool
• Enough Evidence Tying AndroGel To Heart Attacks, Jury Hears
• FDA Says Lead Blood Test Firm Didn't Report Complaints
• Shkreli Like The Pied Piper, Retrophin CEO Tells Jury
• EU Court Adviser Sides With German Drugmaker In VAT Fight
• Investor Says AMRI's Go-Private Deal Docs Short On Details
• Mylan Can't Move Sanofi's EpiPen Antitrust Suit
• 4 Things To Remember About Refill Reminder Compliance
• Where AI Meets Cybersecurity And The Legal Profession
• Miami Physician Pleads Guilty To Medicare Fraud
• DOJ Arrests 400, Targets Opioids In $1.3B Fraud 'Takedown'
• Why 'Class Action Attorney Fees' Are Such Dirty Words
• 6th Circ. Affirms Class Cert. Denial In Junk Fax Row
• Dr. Reddy's Infringed Horizon's Vimovo Patent, Judge Says
• Shkreli 'Absolutely Stunned' Chairman With Lie
• 3rd Circ. Revives Kidney Disease Treatment Royalties Suit
• Justice Breyer On Changing His Mind And Sparring With Scalia
• Pfizer Assails Janssen Suit Over Remicade Biosimilar
• House Passes Reauthorization Of FDA User Fees
• Stryker Awarded $248M In Post-Halo Patent Remand
• UK Supreme Court Reworks Infringement Test In Eli Lilly Win
• Off-Label Drug Bills Get Little Traction On Capitol Hill
• 'Keurig Of Weed' Suit To Reverse Customs Block Vaporized
• FDA Rejects Ocular Therapeutix Eye Drug
• 3 Takeaways From The FDA Head's New Opioid Rx Standards
• Par Infringed Ferring Colonoscopy Drug IP, Says Del. Judge
• Value-Based Challenges And Opportunities For Pharma Cos.
• Medtronic Case Illustrates High Bar For Inequitable Conduct
• No 'Real Intention To Prosecute' Means Fraudulent Joinder
• Innovating For Wise Juries: Interim Arguments
• Unstructured Data Is Just The Tip Of The Iceberg
• Valeant, Pershing, Investors Battle For Quick Wins In Suit
• Ex-Insys Sales Reps Plead Guilty In Opioid Kickback Scheme
• Justice Breyer On The Limits Of Presidential Power
• CVS Strikes $5M Deal Over Prescription Drug Records
• AIA Sponsor Wants Full Fed. Circ. To Weigh On-Sale Bar Rule
• Shkreli Fund In The Red, Jury Told, As He Boasted Of Millions
• Crucial Expert's Opinion In Doubt For J&J Talc Cancer Trial
• BioScrip Investors Say Chancery Was Wrong To Toss Suit
• Akin Gump Nabs Ex-FDA Deputy Chief
• Judge OKs Settlement In Supplement Co. Junk Fax Row
• $35M Ends US Claims Of Mallinckrodt Link To Opioid Abuse
• FDA Warning Wire: Corroded Equipment At Indian Drug Plant
• FTC Appoints Endo Pay-For-Delay Settlement Monitor
• Walgreens Refutes Customers' Redo Bid In Blood Test Suit
• Momenta Tells Jury Amphastar Ripped Off Drug Patent
• Bayer, J&J Misrepresented Xarelto Risks, Suits Say
• EQT Partners Scoops Up Drug Tech Co. In $850M Deal
• Employees In All But Name: Where's The Privilege?
• LA Leads The Way With Draft Commercial Cannabis Regs
• 5 Questions To Ask Firm Before Accepting A Litigation AFA
• J&J's Talc Supplier Escapes Cancer Trial
• Pulled Pain Pill, Opioid Rates Show Need For Research
• Shkreli's Focus Reminds Investor Of The 'Rain Man'
• McGuireWoods Adds Product Liability Litigator In Dallas
• Ex-FDA Chief Tells Jury AndroGel Ads Were Misleading
• Morgan Lewis Lands Eckert Seamans Atty In Pittsburgh
• Abilify Generics Infringe Otsuka Patent, Fed. Circ. Told
• Unilife Committee Atty Withdraws To Save Firm's Retention
• Bain, Cinven Continue Stada Pursuit With Improved $4.7B Bid
• Ex-Insys Staffer Denied Bid To Use Marijuana Pre-Trial
• Will ACA Repeal Pass? Here's What 11 Experts Think
• Sills Cummis Sues Ex-Client Over Biz Ownership Transfer
• Chocolate Powder Is 'Cocaine On Training Wheels,' FDA Told
• 2 Biotech Cos., Yoga Studio Chain Launch IPOs For $255M
• Novo Gets Sanofi's Insulin Advertising Claims Trimmed
• WaPo Sues DOJ For Opioid Epidemic Docs
• Investors Sue Eye Drug Co. After Manufacturing Issues
• Why Posner Pounced On Eyedrop Class Certification
• Why You Should Argue Your Appeal
• DC Circ. Adds Feather To DEA's Regulatory Authority Hat
• 6 Ways Teaching A Law School Class Can Benefit Lawyers
• Congressional Forecast: July
• Prosthetics Maker Says Shumaker Loop Error Cost It $50M
• Gilead FCA Suit Satisfies Escobar, 9th Circ. Rules
• 6 Shareholder Suits Over Akorn-Fresenius Deal Moved To Ill.
• Teva Targets Ex-Exec Who Dated, Gave Info To Apotex CEO
• Apotex, Ranbaxy End Pay-For-Delay Suit Over Narcolepsy Med
• Bristol-Myers, Pfizer Again Sued Over Eliquis Risks
• Whistleblowers Fight To Keep Medicare Fraud Suit Alive
• Plane Tickets, Voicemails Worry Feds In Insider Trading Case
• Fresenius Asks Judge To Trim Feds' False Claims Suit
• VC-Backed Danish Biotech Zealand Pharma Files $86M US IPO
• Deals Rumor Mill: Elliott Management, Stada, Kind
• Beware Export Controls On Software, Encryption, Technology
• Time To Focus On Cybersecurity In Health Care
• PTAB Nixes AbbVie Patent For $16B Blockbuster Humira
• Ex-Analyst Tells Of 'Depressed' Shkreli After Fund Implosion
• State Classes Get Tag-Team Trials In Syngenta Corn MDL
• Pharmacy Barred From Drug Production Over Contamination
• Generics Lobby Sues To Block Md. Drug Pricing Law
• Konica Minolta To Buy Ambry Genetics In Deal Worth $1B
• Ex-MLB Player Gets Defamation Suit Sent To NY State Court
• AbbVie Tells Jury Studies Don't Tie AndroGel To Heart Attacks
• 8th Circ. Upholds DePuy Quick Win In Hip Implant Suit
• Actavis Reaches Deal With Vivus Over Obesity Drug Patents
• Lawsuit Challenges Fla. Medical Marijuana Smoking Ban
• EU Accuses GE, Others Of Filing Misleading Info On Mergers
• Namenda Wholesalers Fire Back At Teva's Bid To DQ Expert
• Precision Biologics Investor Sues For Custodian, Recovery
• GSK Says Patent Deal Relevant To Abbott HIV Drug Suit
• Sherwin-Williams, Others Look To Dodge Landfill Cleanup Suit
• Covington Snags Undefeated Litigator From O'Melveny
• Bowing To FDA, Endo Halts Opana Painkiller Sales
• Merck's Noxafil Wasn't Revealed Before Invention, Court Told
• FDA Halts 3 Merck Keytruda Studies After Deaths
• Considerations For Entry Into The Marijuana Industry
• Robbins Geller, Johnson & Weaver To Helm Cempra Suit
• Illinois County Sues Drug Cos. Over Role In Opioid Crisis
• Talc Supplier Likely Can't Escape J&J Cancer Trial
• Justice Stevens On Gorsuch And Sticking With The Cubs
• Unilife Creditor Objects To Committee's Counsel Retention
• Shkreli Ordered To Shut Up About Securities Fraud Trial
• AbbVie Sold AndroGel Without Heart Risk Warning, Jury Told
• Feds Fight Ex-MLB Player's Bid For New Insider Trading Trial
• Valeant, Pershing Trying To Hide Behind SEC, Investors Say
• HQ's Heart-Drug Generic Would Flout Baxter Deal, Judge Says
• Venture-Backed Dermatology Co. Files $75M IPO
• Umberg Zipser Boosts IP Group With 2 From Fish & Tsang
• Fed. Circ. Asked To Rehear Patent On-Sale Bar Case En Banc
• FDA Warning Wire: Drugmaker Defiance, Dangerous Dog Food
• Hatch Floats Bill Promoting Rare Disease Treatments
• FDA May Push Boundaries To Speed REMS Negotiations
• Chinese Vaccine Co. Investors Sue After Bribery Report
• Innovating For Wise Juries: Openings Before Voir Dire
• 5 Questions To Ask Client Before Proposing A Litigation AFA
• Justice Stevens On Playing Politics With The High Court
• J&J's McNeil Gets New Trial After $48M Motrin Reaction Loss
• DLA Piper Strengthens Corporate Practice With Cooley Atty
• UnitedHealth Members Fight Bid To Toss Clawback Suit
• Spokeo Doesn't Doom Genetic Privacy Row, Judge Says
• Drugmakers Urge FDA To Phase Out Older Opioids
• Pa. Judge Urged To Move Mesh Cases After Justices' Rulings
• Theranos Wants Class Limited To Indirect Share Purchasers
• Redfin, Clementia Eyeing A Combined $215M In IPOs
• OvaScience Shareholder Attacks Director Compensation Deal
• Bartlit Beck Scores A Trio Of Patent Trial Verdicts
• Fla. Compounding Pharmacy Ripped Off Tricare, Feds Claim
• Teva Wants Ex-Exec DQ'd As Expert In Namenda Buyers' Suit
• A Regulatory Bellwether: Forecasting Cyber Breach Litigation
• Tech, Pharma Divided Over Section 101 Challenges Post-Alice
• Leegin's 10-Year Checkup